Evidence map›Paper›PMID 33009989›Full record

SynthesisNeurosurgical review2021

Safety and efficacy of prothrombin complex concentrate (PCC) for anticoagulation reversal in patients undergoing urgent neurosurgical procedures: a systematic review and metaanalysis.

Harrison Faulkner, Shubham Chakankar, Marco Mammi, Jack Yu Tung Lo, Joanne Doucette, Nawaf Al-Otaibi, Judi Abboud, Andrew Le, Rania A Mekary, Adomas Bunevicius

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Neurosurgical review, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 5 countries.

Harrison FaulknerUniversity of New South Wales, Sydney, NSW, 2052, Australia.
Shubham ChakankarSchool of Pharmacy, MCPHS University, Boston, MA, 02115, USA.
Marco MammiNeurosurgery Unit, Department of Neurosciences, University of Turin, via Cherasco 15, 10126, Turin, Italy.
Jack Yu Tung LoComputational Neuroscience Outcomes Center, Department of Neurosurgery, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA.
Joanne DoucetteSchool of Pharmacy, MCPHS University, Boston, MA, 02115, USA.
Nawaf Al-OtaibiSchool of Pharmacy, MCPHS University, Boston, MA, 02115, USA.
Judi AbboudSchool of Pharmacy, MCPHS University, Boston, MA, 02115, USA.
Andrew LeSchool of Pharmacy, MCPHS University, Boston, MA, 02115, USA.
Rania A MekarySchool of Pharmacy, MCPHS University, Boston, MA, 02115, USA. rania.mekary@mcphs.edu.ORCID http://orcid.org/0000-0003-1636-0759
Adomas BuneviciusLithuanian University of Health Sciences, Kaunas, Lithuania.
Massachusetts College of Pharmacy and Health Sciences · USBrigham and Women's Hospital · USLithuanian University of Health Sciences · LTUniversity of Turin · ITUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anticoagulant therapy poses a significant risk for patients undergoing emergency neurosurgery procedures, necessitating reversal with prothrombin complex concentrate (PCC) or fresh frozen plasma (FFP). Data on PCC efficacy lack consistency in this setting. This systematic review and metaanalysis aimed to evaluate efficacy and safety of PCC for anticoagulation reversal in the context of urgent neurosurgery. Articles from PubMed, Embase, and Cochrane databases were screened according to the PRISMA checklist. Adult patients receiving anticoagulation reversal with PCC for emergency neurosurgical procedures were included. When available, patients who received FFP were included as a comparison group. Pooled estimates of observational studies were calculated for efficacy and safety outcomes via random-effects modeling. Initial search returned 4505 articles, of which 15 studies met the inclusion criteria. Anticoagulants used included warfarin (83%), rivaroxaban (6.8%), phenprocoumon (6.1%), apixaban (2.2%), and dabigatran (1.5%). The mean International Normalized Ratio (INR) prePCC administration ranged from 2.3 to 11.7, while postPCC administration from 1.1 to 1.4. All-cause mortality at 30 days was 27% (95%CI 21, 34%; I

Indexed as

AnticoagulantsBlood Coagulation FactorsHumansInternational Normalized RatioRetrospective StudiesWarfarinAnticoagulantsBlood Coagulation Factorsprothrombin complex concentratesWarfarinMetaanalysisNeurosurgeryNeurosurgical proceduresProthrombin complex concentrate (PCC)

Identifiers

PMID33009989
OpenAlexW3091658634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.